Comparison and discussion of the treatment guidelines for small cell lung cancer
Small cell lung cancer (SCLC), which accounts for 15% to 17% of all lung cancers, is one of the leading causes of cancer‐related death worldwide. More than 130 000 new diagnoses of SCLC and 100 000 deaths from the disease were estimated to have occurred in China in 2013. The existing guidelines of S...
Gespeichert in:
| Veröffentlicht in: | Thoracic cancer 2018-07, Vol.9 (7), p.769-774 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 774 |
|---|---|
| container_issue | 7 |
| container_start_page | 769 |
| container_title | Thoracic cancer |
| container_volume | 9 |
| creator | Zhao, Honglin Ren, Dian Liu, Hongyu Chen, Jun |
| description | Small cell lung cancer (SCLC), which accounts for 15% to 17% of all lung cancers, is one of the leading causes of cancer‐related death worldwide. More than 130 000 new diagnoses of SCLC and 100 000 deaths from the disease were estimated to have occurred in China in 2013. The existing guidelines of SCLC therapeutic principles differ by region. In recent years, new immunotherapy and targeted therapy treatments have been lacking. In order to understand the current status of SCLC treatment in more detail, we identified the similarities and differences among the latest National Comprehensive Cancer Network Clinical Practice Guidelines for SCLC, the Chinese Society of Clinical Oncology Lung Cancer Guidelines, and the European Society for Medical Oncology Clinical Practice Guidelines for Metastatic SCLC, and present a reference of treatment strategies that should prove beneficial for the treatment of patients with SCLC. |
| doi_str_mv | 10.1111/1759-7714.12765 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6026606</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A737118644</galeid><sourcerecordid>A737118644</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6005-c519a8a7b19831f76383826cd8d9b1c22cac43bcac2516dc43f4c4d8c95628d53</originalsourceid><addsrcrecordid>eNqFUt9rHCEQltKShDTPeStCX_pyF3XXXy-F42iTQqB5SJ_FU_di2NWr7jbkv-9sL702pZARdJz55hvHGYTOKVlSkAsquV5ISdslZVLwV-jkYHl90Ik4Rme13hOQRmnC-BE6ZhocXMsTdLPOw86WWHPCNnnsY3VTrRGuucPjXcBjCXYcQhrxdoo-9DGFirtccB1s32MXYOuntMXOJhfKW_Sms30NZ0_nKfr2-dPt-mpx_fXyy3p1vXCCEL5wnGqrrNxQrRraSdGoRjHhvPJ6Qx1jzrq22cDOOBUe9K51rVdOc8GU580p-rjn3U2bIXgHDyy2N7sSB1seTbbRPPekeGe2-YcRhAlBBBB8eCIo-fsU6mgGqB2qsSnkqRpGWiKFaOQMff8P9D5PJUF5hjGtpVaMqj-ore2DianLkNfNpGYlG0mpEm0LqOV_ULB8GKLLKXQR7M8CLvYBruRaS-gONVJi5jkwc6fN3HXzaw4g4t3fX3PA_-46APge8AC5Hl_iM7fr1Z74J68Fu1g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2299798218</pqid></control><display><type>article</type><title>Comparison and discussion of the treatment guidelines for small cell lung cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Zhao, Honglin ; Ren, Dian ; Liu, Hongyu ; Chen, Jun</creator><creatorcontrib>Zhao, Honglin ; Ren, Dian ; Liu, Hongyu ; Chen, Jun</creatorcontrib><description>Small cell lung cancer (SCLC), which accounts for 15% to 17% of all lung cancers, is one of the leading causes of cancer‐related death worldwide. More than 130 000 new diagnoses of SCLC and 100 000 deaths from the disease were estimated to have occurred in China in 2013. The existing guidelines of SCLC therapeutic principles differ by region. In recent years, new immunotherapy and targeted therapy treatments have been lacking. In order to understand the current status of SCLC treatment in more detail, we identified the similarities and differences among the latest National Comprehensive Cancer Network Clinical Practice Guidelines for SCLC, the Chinese Society of Clinical Oncology Lung Cancer Guidelines, and the European Society for Medical Oncology Clinical Practice Guidelines for Metastatic SCLC, and present a reference of treatment strategies that should prove beneficial for the treatment of patients with SCLC.</description><identifier>ISSN: 1759-7706</identifier><identifier>EISSN: 1759-7714</identifier><identifier>DOI: 10.1111/1759-7714.12765</identifier><identifier>PMID: 29770597</identifier><language>eng</language><publisher>Melbourne: John Wiley & Sons Australia, Ltd</publisher><subject>Bendamustine ; Brain research ; Cancer therapies ; Care and treatment ; Chemotherapy ; China - epidemiology ; Clinical medicine ; Clinical trials ; Epidemiology ; Guidelines ; Guidelines as Topic ; Health aspects ; Humans ; Immunotherapy ; Ipilimumab ; Lung cancer ; Lung cancer, Small cell ; Medical diagnosis ; Medical imaging ; Medical research ; Medicine, Experimental ; Metastasis ; Mini Review ; Mini Reviews ; Molecular Targeted Therapy ; Neoplasm Metastasis ; NMR ; Nuclear magnetic resonance ; Oncology ; Patient compliance ; Radiation therapy ; small cell lung cancer (SCLC) ; Small Cell Lung Carcinoma - drug therapy ; Small Cell Lung Carcinoma - genetics ; Small Cell Lung Carcinoma - pathology ; treatment</subject><ispartof>Thoracic cancer, 2018-07, Vol.9 (7), p.769-774</ispartof><rights>2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd</rights><rights>2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.</rights><rights>COPYRIGHT 2018 John Wiley & Sons, Inc.</rights><rights>2018. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6005-c519a8a7b19831f76383826cd8d9b1c22cac43bcac2516dc43f4c4d8c95628d53</citedby><cites>FETCH-LOGICAL-c6005-c519a8a7b19831f76383826cd8d9b1c22cac43bcac2516dc43f4c4d8c95628d53</cites><orcidid>0000-0002-2362-5359</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026606/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026606/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11542,27903,27904,45553,45554,46031,46455,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29770597$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Honglin</creatorcontrib><creatorcontrib>Ren, Dian</creatorcontrib><creatorcontrib>Liu, Hongyu</creatorcontrib><creatorcontrib>Chen, Jun</creatorcontrib><title>Comparison and discussion of the treatment guidelines for small cell lung cancer</title><title>Thoracic cancer</title><addtitle>Thorac Cancer</addtitle><description>Small cell lung cancer (SCLC), which accounts for 15% to 17% of all lung cancers, is one of the leading causes of cancer‐related death worldwide. More than 130 000 new diagnoses of SCLC and 100 000 deaths from the disease were estimated to have occurred in China in 2013. The existing guidelines of SCLC therapeutic principles differ by region. In recent years, new immunotherapy and targeted therapy treatments have been lacking. In order to understand the current status of SCLC treatment in more detail, we identified the similarities and differences among the latest National Comprehensive Cancer Network Clinical Practice Guidelines for SCLC, the Chinese Society of Clinical Oncology Lung Cancer Guidelines, and the European Society for Medical Oncology Clinical Practice Guidelines for Metastatic SCLC, and present a reference of treatment strategies that should prove beneficial for the treatment of patients with SCLC.</description><subject>Bendamustine</subject><subject>Brain research</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>China - epidemiology</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Epidemiology</subject><subject>Guidelines</subject><subject>Guidelines as Topic</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Ipilimumab</subject><subject>Lung cancer</subject><subject>Lung cancer, Small cell</subject><subject>Medical diagnosis</subject><subject>Medical imaging</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Metastasis</subject><subject>Mini Review</subject><subject>Mini Reviews</subject><subject>Molecular Targeted Therapy</subject><subject>Neoplasm Metastasis</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Oncology</subject><subject>Patient compliance</subject><subject>Radiation therapy</subject><subject>small cell lung cancer (SCLC)</subject><subject>Small Cell Lung Carcinoma - drug therapy</subject><subject>Small Cell Lung Carcinoma - genetics</subject><subject>Small Cell Lung Carcinoma - pathology</subject><subject>treatment</subject><issn>1759-7706</issn><issn>1759-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqFUt9rHCEQltKShDTPeStCX_pyF3XXXy-F42iTQqB5SJ_FU_di2NWr7jbkv-9sL702pZARdJz55hvHGYTOKVlSkAsquV5ISdslZVLwV-jkYHl90Ik4Rme13hOQRmnC-BE6ZhocXMsTdLPOw86WWHPCNnnsY3VTrRGuucPjXcBjCXYcQhrxdoo-9DGFirtccB1s32MXYOuntMXOJhfKW_Sms30NZ0_nKfr2-dPt-mpx_fXyy3p1vXCCEL5wnGqrrNxQrRraSdGoRjHhvPJ6Qx1jzrq22cDOOBUe9K51rVdOc8GU580p-rjn3U2bIXgHDyy2N7sSB1seTbbRPPekeGe2-YcRhAlBBBB8eCIo-fsU6mgGqB2qsSnkqRpGWiKFaOQMff8P9D5PJUF5hjGtpVaMqj-ore2DianLkNfNpGYlG0mpEm0LqOV_ULB8GKLLKXQR7M8CLvYBruRaS-gONVJi5jkwc6fN3HXzaw4g4t3fX3PA_-46APge8AC5Hl_iM7fr1Z74J68Fu1g</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Zhao, Honglin</creator><creator>Ren, Dian</creator><creator>Liu, Hongyu</creator><creator>Chen, Jun</creator><general>John Wiley & Sons Australia, Ltd</general><general>John Wiley & Sons, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2362-5359</orcidid></search><sort><creationdate>201807</creationdate><title>Comparison and discussion of the treatment guidelines for small cell lung cancer</title><author>Zhao, Honglin ; Ren, Dian ; Liu, Hongyu ; Chen, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6005-c519a8a7b19831f76383826cd8d9b1c22cac43bcac2516dc43f4c4d8c95628d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Bendamustine</topic><topic>Brain research</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>China - epidemiology</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Epidemiology</topic><topic>Guidelines</topic><topic>Guidelines as Topic</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Ipilimumab</topic><topic>Lung cancer</topic><topic>Lung cancer, Small cell</topic><topic>Medical diagnosis</topic><topic>Medical imaging</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Metastasis</topic><topic>Mini Review</topic><topic>Mini Reviews</topic><topic>Molecular Targeted Therapy</topic><topic>Neoplasm Metastasis</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Oncology</topic><topic>Patient compliance</topic><topic>Radiation therapy</topic><topic>small cell lung cancer (SCLC)</topic><topic>Small Cell Lung Carcinoma - drug therapy</topic><topic>Small Cell Lung Carcinoma - genetics</topic><topic>Small Cell Lung Carcinoma - pathology</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Honglin</creatorcontrib><creatorcontrib>Ren, Dian</creatorcontrib><creatorcontrib>Liu, Hongyu</creatorcontrib><creatorcontrib>Chen, Jun</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Thoracic cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Honglin</au><au>Ren, Dian</au><au>Liu, Hongyu</au><au>Chen, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison and discussion of the treatment guidelines for small cell lung cancer</atitle><jtitle>Thoracic cancer</jtitle><addtitle>Thorac Cancer</addtitle><date>2018-07</date><risdate>2018</risdate><volume>9</volume><issue>7</issue><spage>769</spage><epage>774</epage><pages>769-774</pages><issn>1759-7706</issn><eissn>1759-7714</eissn><abstract>Small cell lung cancer (SCLC), which accounts for 15% to 17% of all lung cancers, is one of the leading causes of cancer‐related death worldwide. More than 130 000 new diagnoses of SCLC and 100 000 deaths from the disease were estimated to have occurred in China in 2013. The existing guidelines of SCLC therapeutic principles differ by region. In recent years, new immunotherapy and targeted therapy treatments have been lacking. In order to understand the current status of SCLC treatment in more detail, we identified the similarities and differences among the latest National Comprehensive Cancer Network Clinical Practice Guidelines for SCLC, the Chinese Society of Clinical Oncology Lung Cancer Guidelines, and the European Society for Medical Oncology Clinical Practice Guidelines for Metastatic SCLC, and present a reference of treatment strategies that should prove beneficial for the treatment of patients with SCLC.</abstract><cop>Melbourne</cop><pub>John Wiley & Sons Australia, Ltd</pub><pmid>29770597</pmid><doi>10.1111/1759-7714.12765</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-2362-5359</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1759-7706 |
| ispartof | Thoracic cancer, 2018-07, Vol.9 (7), p.769-774 |
| issn | 1759-7706 1759-7714 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6026606 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Bendamustine Brain research Cancer therapies Care and treatment Chemotherapy China - epidemiology Clinical medicine Clinical trials Epidemiology Guidelines Guidelines as Topic Health aspects Humans Immunotherapy Ipilimumab Lung cancer Lung cancer, Small cell Medical diagnosis Medical imaging Medical research Medicine, Experimental Metastasis Mini Review Mini Reviews Molecular Targeted Therapy Neoplasm Metastasis NMR Nuclear magnetic resonance Oncology Patient compliance Radiation therapy small cell lung cancer (SCLC) Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - genetics Small Cell Lung Carcinoma - pathology treatment |
| title | Comparison and discussion of the treatment guidelines for small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T11%3A59%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20and%20discussion%20of%20the%20treatment%20guidelines%20for%20small%20cell%20lung%20cancer&rft.jtitle=Thoracic%20cancer&rft.au=Zhao,%20Honglin&rft.date=2018-07&rft.volume=9&rft.issue=7&rft.spage=769&rft.epage=774&rft.pages=769-774&rft.issn=1759-7706&rft.eissn=1759-7714&rft_id=info:doi/10.1111/1759-7714.12765&rft_dat=%3Cgale_pubme%3EA737118644%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2299798218&rft_id=info:pmid/29770597&rft_galeid=A737118644&rfr_iscdi=true |